Abstracts tagged "Epidemiologic methods"

Abstract Number: 1440 • 2018 ACR/ARHP Annual Meeting
Systemic Sclerosis in Pediatric Patients: An Epidemiological Study in a Large Insured Population in the US
Alexander Michel¹, Marcela Rivera², Tatsiana Vaitsiakhovich², Simon Teal² and Janethe Pena³, ¹Epidemiology, Bayer Basel, Basel, Switzerland, ²Real World Evidence, Bayer AG, Berlin, Germany, ³Clinical Development, Bayer US LLC, Whippany, NJ
Background/Purpose: Systemic sclerosis (SSc) is a very rare autoimmune disorder and only very few population-based epidemiological studies described its incidence and prevalence in children. In…
Abstract Number: 2766 • 2018 ACR/ARHP Annual Meeting
Seasonal Variation in Incidence of Giant Cell Arteritis: A Population-Based Cohort Study
Shafay Raheel¹, Cynthia S. Crowson² and Eric L. Matteson³, ¹St. Joseph's Hospital, Chicago, IL, ²Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN
Background/Purpose: To determine whether there is a seasonal peak onset of giant cell arteritis (GCA). We examined the seasonal variability of GCA in a geographically-defined…
Abstract Number: 274 • 2018 ACR/ARHP Annual Meeting
Socioeconomic Disparities in Disease Activity in Patients with Rheumatoid Arthritis
Lei Zhu¹, Evelyn Talbott² and Larry W. Moreland¹, ¹Division of Rheumatology and Clinical Immunology, Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, ²Epidemiology, University of Pittsbugh, Pittsburgh, PA
Background/Purpose: To develop a methodology for well-defined rheumatoid arthritis (RA) measurement as an outcome and provide a clear definition of social determinants related to disease…
Abstract Number: 1494 • 2018 ACR/ARHP Annual Meeting
Predictors of Persistence to Methotrexate Treatment in RA – Assessment of Different Modelling Approaches
Helga Westerlind¹, Mateusz Maciejewski², Thomas Frisell³, Scott Jelinsky⁴, Daniel Ziemek⁵ and Johan Askling¹, ¹Unit of Clinical Epidemiology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ²Systems Immunology, Inflammation & Immunology,, Pfizer, Cambridge, MA, ³Clinical Epidemiology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ⁴Inflammation and Immunology, Pfizer Research and Development, Cambridge, MA, ⁵Systems Immunology, Inflammation & Immunology,, Pfizer, Berlin, Germany
Background/Purpose: As a step towards personalized medicine, we seek to identify patients with new-onset RA who are likely to remain well on MTX monotherapy. Patients…
Abstract Number: 2817 • 2018 ACR/ARHP Annual Meeting
Cardiovascular Disease Risk with Biologics and Tofacitinib Compared to Conventional Synthetic Dmards in Patients with Rheumatoid Arthritis
Gulsen Ozen¹, Sofia Pedro² and Kaleb Michaud^1,2, ¹Rheumatology, University of Nebraska Medical Center, Omaha, NE, ²FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS
Background/Purpose: Cardiovascular disease (CVD) represents the leading cause of death in RA, accounting for ~50% of excess mortality. Disease activity, strongly linked to CVD, has…
Abstract Number: 537 • 2018 ACR/ARHP Annual Meeting
Increased Risk of Incident Chronic Kidney Disease Among Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Cohort Studies
Patompong Ungprasert¹ and Sukit Raksasuk², ¹Clinical Epidemiology Unit, Department of Research and Development, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, ²Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
Increased Risk of Incident Chronic Kidney Disease among Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis of Cohort Studies AbstractBackground/Purpose: Patients with rheumatoid arthritis (RA)…
Abstract Number: 1611 • 2018 ACR/ARHP Annual Meeting
Hospitalizations for Serious Infections in Psoriatic Arthritis Patients: Data from the National Inpatient Sample 2000-2014
Paras Karmacharya¹, Cynthia S. Crowson², Dilli Poudel³, Pragya Shrestha⁴ and Kerry Wright⁵, ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Internal Medicine, Reading Hospital-Tower Health System, WEST READING, PA, ⁴Internal medicine, Reading Hospital-Tower Health System, West Reading, PA, ⁵Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Increased risk of infections has been recognized in patients with psoriatic arthritis (PsA) compared to those without PsA. Immunomodulatory effects of PsA, immunosuppressive therapies…
Abstract Number: 2857 • 2018 ACR/ARHP Annual Meeting
An Electronic Audit, Reporting, and Data Correction System Improves the Quantity and Quality of Observational Data Collected for US Veterans Enrolled in the Veterans Affairs Rheumatoid Arthritis Registry
Grant W. Cannon^1,2, Jorge Rogas², Neill Bell³, Joshua Baker⁴, Gail S. Kerr⁵, Angelo Gaffo⁶, J. Steuart Richards⁷, Jennifer Barton⁸, Pascale Schwab⁸, Ted R. Mikuls⁹, Namrata Singh¹⁰, Liron Caplan¹¹, Deana Lazaro¹², Andreas Reimold¹³ and Brian Sauer², ¹Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ²Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ³Salt Lake City VA Medical Center and University of Utah, Dallas VA Medical Center, Dallas, TX, ⁴Philadelphia VA Medical Center and University of Pennsylvania, Philadelphia, PA, ⁵Washington VA Medical Center, Georgetown and Howard Universities, Washington, DC, ⁶Birmingham VA and University of Alabama at Birmingham, Birmingham, AL, ⁷Pittsburgh VA Medical Center and University of Pittsburgh, Pittsburgh, PA, ⁸VA Portland Health Care System and Oregon Health and Science, Portland, OR, ⁹VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ¹⁰Internal Medicine, Iowa City VA Medical Center and University of Iowa, Iowa City, IA, ¹¹Div of Rheumatology, Denver VA Medical Center and University of Colorado, Aurora, CO, ¹²Brooklyn VA Medical Center and SUNY Downstate, Brooklyn, NY, ¹³Rheumatology, Dallas VA Medical Center and University of Texas - Southwestern, Dallas, TX
Background/Purpose: The Veterans Affairs (VA) Rheumatoid Arthritis (RA) (VARA) registry is an observational cohort study of US Veterans with RA at 11 VA Medical…
Abstract Number: 640 • 2018 ACR/ARHP Annual Meeting
Increasing Rates of Arthroplasty for Psoriatic Arthritis in the United Kingdom between 1995 and 2010
Ryan Lewinson¹, Isabelle Vallerand², Jeremy LaMothe³, Laurie Parsons¹, Alexandra Frolkis⁴, Mark Lowerison², Scott Patten² and Cheryl Barnabe^2,5, ¹Dermatology, University of Calgary, Calgary, AB, Canada, ²Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ³Orthopaedic Surgery, University of Calgary, Calgary, AB, Canada, ⁴Internal Medicine, University of Calgary, Calgary, AB, Canada, ⁵Division of Rheumatology, University of Calgary, Calgary, AB, Canada
Background/Purpose: Arthroplasty requirements among patients with psoriatic arthritis (PsA) are not well known. This information is of importance to clinical and policy stakeholders for health…
Abstract Number: 2144 • 2018 ACR/ARHP Annual Meeting
Epidemiological Characterisitics of Psoriatric Arthritis: A Nationwide Study of Inpatient Hospitalisations in 2014
Vagishwari Murugesan and Jennifer Tran, Internal Medicine, Medstar Washington Hospital Center, Washington, DC
Background/Purpose:: Psoriatic arthritis is a seronegative inflammatory arthritis associated with Psoriasis. Using the National Inpatient Sample (NIS) we studied the epidemiological characteristics of inpatients admissions…
Abstract Number: 2896 • 2018 ACR/ARHP Annual Meeting
Increased Mortality Among Patients with Systemic Lupus Erythematosus after Hydroxychloroquine Discontinuation
April Jorge¹, Na Lu^2,3, Eric C. Sayre³, Hamid Tavakoli⁴, Natalie McCormick⁵, John M. Esdaile^3,6, Mary DeVera⁵, Hyon K. Choi¹ and J. Antonio Avina-Zubieta⁷, ¹Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Arthritis Research Canada, Richmond, BC, Canada, ⁴Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, ⁵Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, ⁶Department of Medicine, Division of Rheumatology, University of British Columbia, Vancouver, BC, Canada, ⁷Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Hydroxychloroquine (HCQ) is near-universally recommended for patients with SLE. Use of this medication has previously been associated with a substantial survival benefit among SLE…
Abstract Number: 673 • 2018 ACR/ARHP Annual Meeting
Chronic Back Pain (CBP) in First Degree Relatives (FDRs) of Patient with Ankylosing Spondylitis (AS): Comparison with the US Population, HLA-B27 Frequency and Persistence of Symptoms over Time
John D. Reveille¹, MinJae Lee², Laura A. Diekman³, Michael Ward⁴, Lianne S. Gensler⁵, Amirali Tahanan², Mohammad H. Rahbar⁶ and Michael Weisman⁷, ¹McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, ²Biostatistics/Epidemiology/Research Design (BERD) Core | Center for Clinical and Translational Sciences, University of Texas-McGovern Medical School, Houston, TX, ³Rheumatology, McGovern Medical School at the University of Texas Health Science Center at Houston, USA, Houston, TX, ⁴National Institutes of Health, Bethesda, MD, USA, Bethesda, MD, ⁵University of California San Francisco, San Francisco, CA, ⁶Biostatistics/Epidemiology/Research Design (BERD) Core | Center for Clinical and Translational Sciences, McGovern Medical School at the University of Texas Health Science Center at Houston, USA, Houston, TX, ⁷Harbor UCLA Medical Center, Los Angeles, CA
Background/Purpose: We examined first degree relatives (FDRs) of patients with ankylosing spondylitis (AS) patients with chronic inflammatory back pain (CIBP), non-inflammatory CBP (NICBP) and no…
Abstract Number: 2145 • 2018 ACR/ARHP Annual Meeting
Increased Risk of Heart Failure with Prolonged Use of Hydroxychloroquine in Patients with Rheumatoid Arthritis
Elena Myasoedova¹, Reto Kurmann², Cynthia S. Crowson³, John M. Davis III¹ and Rekha Mankad², ¹Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, ²Cardiovascular Diseases, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN
Background/Purpose: Hydroxychloroquine (HCQ) is commonly prescribed for patients with rheumatoid arthritis (RA). Cardiotoxicity is a rare but potentially life-threatening side effect of HCQ and may…
Abstract Number: 2924 • 2018 ACR/ARHP Annual Meeting
Spinal Radiographic Progression in Early Axial Spondyloarthritis: 5-Year Data from the DESIR Cohort
Sofia Ramiro¹, Désirée van der Heijde², Alexandre Sepriano³, Miranda van Lunteren⁴, Anna Molto⁵, Maria Antonietta D'Agostino⁶, Damien Loeuille⁷, Maxime Dougados⁸, M. Reijnierse⁹ and Pascal Claudepierre¹⁰, ¹Zuyderland Medical Center, Heerlen & Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Centre, Leiden, Netherlands, ³Leiden University Medical Center, Leiden, Netherlands, ⁴Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Hôpital Cochin, Department of Rheumatology, Paris Descartes University, Paris, France, ⁶Department of Rheumatology, Assistance publique-Hôpitaux de Paris Ambroise Paré Hospital, Boulogne-Billancourt , Université Versailles Saint Quentin en Yvelines, Paris, France, ⁷Rheumatology, University Hospital of Nancy, NANCY, France, ⁸Department of Rheumatology, Paris Descartes University and Cochin Hospital, Paris, France, ⁹Radiology, Leiden University Medical Center, Leiden, Netherlands, ¹⁰Hôpital Henri Mondor, Créteil, France
Background/Purpose: Spinal radiographic progression has been investigated in patients with r-axSpA, but not yet as thoroughly in early axSpA. We aimed to analyse the progression…
Abstract Number: 941 • 2018 ACR/ARHP Annual Meeting
Causal Inference Methods for the Effect of Rheumatoid Arthritis on Mortality Independent of Lifestyle and Clinical Factors before and after RA Diagnosis
Jeffrey A. Sparks¹, Kazuki Yoshida^1,2, Tzu-Chieh Lin³, Carlos Camargo⁴, Benjamin Raby⁵, Hyon K. Choi⁶, Medha Barbhaiya⁷, Sara K. Tedeschi¹, Bing Lu⁸, Karen Costenbader¹ and Elizabeth Karlson¹, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Harvard T.H. Chan School of Public Health, Boston, MA, ³Amgen, Thousand Oaks, CA, ⁴Emergency Medicine, Massachusetts General Hospital, Boston, MA, ⁵Pulmonary, Brigham and Women's Hospital, Boston, MA, ⁶Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, ⁷Rheumatology, Hospital for Special Surgery, New York, NY, ⁸Division of Rheumatology, Immunology and Allergy, Brigham & Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: RA is associated with increased total, cardiovascular, and respiratory mortality compared to the general population. This excess RA mortality may be mediated through lifestyle,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.